|
Characteristic
|
No. subjects
|
|---|
|
Time point 1 (t1)a
|
Time point 2 (t2)b
|
|---|
|
Aspirin regular usec
|
|
Nonuserd
|
14 (45%)
|
11 (35%)
|
|
Long-term user (≥ 2 year)e
|
17 (55%)
|
20 (65%)
|
|
Age
|
50–70 (median 55)
|
60–80 (median 65)
|
|
BMIf
| | |
|
Normal (18.5–25)
|
16 (52%)
|
14 (45%)
|
|
High (≥ 26)
|
15 (48%)
|
17 (55%)
|
|
Polyps
|
|
No polyps
|
18 (58%)
|
23 (74%)
|
|
Yes
|
13 (42%)
|
8 (26%)
|
|
Proximalg
|
|
Tubular adenoma
|
3 (23%)
|
1 (12.5%)
|
|
Serrated lesionh
|
1 (8%)
|
0 (0%)
|
|
Hyperplastic
|
1 (8%)
|
0 (0%)
|
|
Serrated adenoma
|
0 (0%)
|
0 (0%)
|
|
Mixed
|
0 (0%)
|
1 (12.5%) TA and SA
|
|
distali
|
|
Tubular adenoma
|
4 (31%)
|
4 (50%)
|
|
Serrated lesion
|
5 (38%)
|
0 (0%)
|
|
Hyperplastic
|
4 (31%)
|
0 (0%)
|
|
Serrated adenoma
|
1 (7%)
|
0 (0%)
|
|
Mixed
|
0 (0%)
|
1 (12.5%) TA and HP
|
|
Proximal and distal
|
0 (0%)
|
1 (12.5%) TA
|
- aBaseline time point
- b10-year follow-up
- cRegular use defined as ≥ 2 tablets/week for ≥ 1 month
- dNonuser: women who indicated that they did not use the aspirin ≥ 2 tablets/week for ≥ 1 month (“minimum level”)
- eLong-term user: women who indicated that they used the aspirin ≥ 2 tablets/week for ≥ 2 years
- fBMI: body mass index; height (cm) and weight (kg) were self-reported and BMI was calculated (kg/m2) from these variables
- gProximal: cecum
- hSerrated lesion: any serrated polyp including hyperplastic and serrated adenoma
- iDistal: sigmoid colon
